

Cell, Volume 185

Supplemental information

SARS-CoV-2 vaccination induces immunological

T cell memory able to cross-recognize

variants from Alpha to Omicron

Alison Tarke, Camila H. Coelho, Zeli Zhang, Jennifer M. Dan, Esther Dawen Yu, Nils Methot, Nathaniel I. Bloom, Benjamin Goodwin, Elizabeth Phillips, Simon Mallal, John Sidney, Gilberto Filaci, Daniela Weiskopf, Ricardo da Silva Antunes, Shane Crotty, Alba Grifoni, and Alessandro Sette

Table S1. Related to Figures 1, 2, 3, 5 and 6. Characteristics of the donor cohorts enrolled in this study.

	Early COVID-19 (n=16)	mRNA-1273 (n=33)	BNT162b2 (n=27)	Ad26.COVS.2.S (n=28)	NVX-CoV2373 (n=8)
Age (years)					
Range;	27-68;	21-78;	24-66;	20-70	18-60
Median ± IQR	44±40	42±29	36±34	50±27	35±26
Gender					
Male (%)	44% (7/16)	29% (6/21)	40% (8/20)	43% (13/28)	62% (5/8)
Female (%)	56% (9/16)	71% (15/21)	60% (12/20)	57% (15/28)	38% (3/8)
Race or Ethnicity					
White	88% (14/16)	61% (20/33)	48% (13/27)	71% (20/28)	75% (6/8)
Hispanic or Latino	6% (1/16)	21% (7/33)	22% (6/27)	18% (5/28)	13% (1/8)
Asian	0% (0/16)	6% (2/33)	22% (6/27)	4% (1/28)	0% (0/8)
Black	0% (0/16)	3% (1/33)	4% (1/27)	0% (0/28)	0% (0/8)
More than one	0% (0/16)	9% (3/33)	4% (1/27)	7% (2/28)	0% (0/8)
Not reported	6% (1/16)	0% (0/33)	0% (0/27)	0% (0/28)	0% (0/8)
Days post symptoms onset	21-43; 33±29	-	-	-	-
Timepoint 1					
# of donors	n=16	After 1 st dose n=20	After 1 st dose n=20	After 1 st dose n=12	
dPV ^a Range;	-	4-21;	10-52;	14-21;	-
Median ± IQR	-	15±2	15±4	14±1	
RBD IgG positive(%)	100%(16/16)	95%	95%	58%	
N IgG positive(%)	-	0%	5%	0%	
Timepoint 2					
# of donors		After 2 nd dose n=20	After 2 nd dose n=20	After 1 st dose n=12	
dPV ^a Range;	-	13-20;	08-19;	39-68;	-
Median ± IQR	-	14±2	14±1	42±9	
RBD IgG positive(%)		100%	100%	67%	
N IgG positive(%)		0%	5%	8%	
Timepoint 3					
# of donors		After 2 nd dose n=12	After 2 nd dose n=15	After 1 st dose n=15	After 1 st dose n=8
dPV ^a Range;	-	58-86	54-98	102-108	22-90
Median ± IQR	-	77±4	84±5	105±2	78±11
RBD IgG positive(%)		100%	94%	86%	88%
N IgG positive(%)		0%	7%	14%	0%
Timepoint 4					
# of donors		After 2 nd dose n=9	After 2 nd dose n=4		
dPV ^a Range;	-	151-229	169-187	-	-
Median ± IQR	-	175±66	179±12		
RBD IgG positive(%)		100%	100%		
N IgG positive(%)		0%	0%		

^a Samples corresponding to the first and second time point are longitudinal samples from the same donors, while samples from time point 3 and 4 are cross-sectional samples derived from additional independent donors.

Table S3. Related to Figures 1-6. List of amino acid mutations for each SARS-CoV-2 variant.

Protein	Position	Wuhan	B.1.1.7	B.1.351	P.1	B.1.1.519	B.1.617.1	B.1.617.2	C.37	R.1	B.1.427/429	B.1.525	B.1.526	B.1.526.1	B.1.621	B.1.529
E	21	L										F				
E	71	P		L												
M	3	D														G
M	19	Q														E
M	28	F								L						T
M	63	A														
M	162	K		N												
N	3	D	L													
N	12	A										G				
N	13	P		S					L							L
N	31	E														-
N	32	R		H												-
N	33	S														-
N	63	D					G									
N	80	P			R											
N	187	S								L						
N	203	R	K		K	K	M	M		K	K					K
N	204	G	R		R	R				R	R					R
N	205	T													I	
N	212	G		C												
N	214	G							C							
N	234	M									I		I	I		
N	235	S	F													
N	377	D				Y	Y									
N	418	Q								H						
nsp1	109	P		S												
nsp2	85	T		I							I		I	I		
nsp2	339	G		S												
nsp2	366	S		T												
nsp2	427	Q		H												
nsp2	563	E		D												
nsp3	38	K														R
nsp3	141	P				S										
nsp3	183	T	I													
nsp3	186	T			A											
nsp3	237	T													A	
nsp3	370	S			L											
nsp3	720	T													I	
nsp3	778	P									S					
nsp3	837	K		N												
nsp3	890	A	D													
nsp3	926	C		S												
nsp3	977	K			Q											
nsp3	1069	V														I
nsp3	1180	T		I												
nsp3	1189	T										I				-
nsp3	1265	S														I
nsp3	1266	L														
nsp3	1412	I	T													
nsp3	1429	T				N										
nsp3	1469	P					S		S	V						
nsp3	1569	F														
nsp3	1778	N		S												
nsp3	1892	A														T
nsp4	395	S									T					
nsp4	399	K														
nsp4	438	L							P			P	E	P	V	
nsp4	446	A														
nsp4	492	T				I			I						I	I
nsp5	90	K		R												
nsp5	132	P														H
nsp5	193	A		V												
nsp6	49	I				V										
nsp6	77	T					A									
nsp6	106	S	-	-	-							-	-	-		-
nsp6	107	G	-	-	-							-	-	-		-
nsp6	108	F	-	-	-							-	-	-		-
nsp6	125	L									F					
nsp6	135	G		S												
nsp6	149	V		F												
nsp6	160	Q													R	
nsp6	167	L									F					
nsp6	189	A														V
nsp6	278	V												I		
nsp9	35	T				I										
nsp10	105	N		K												
nsp12	314	N							L	L						
nsp12	323	P	L	L	L	L	L	L			L	F	L	L	L	I
nsp12	671	G						S								
nsp13	53	P									L					
nsp13	77	P					L									
nsp13	88	Q											H	H		
nsp13	209	V									F					
nsp13	260	D									Y					
nsp13	341	E			D											
nsp13	419	P													S	
nsp13	429	M					I									
nsp13	439	G								R						
nsp13	588	T		I												
nsp14	42	I														V
nsp14	177	L		F												
nsp14	326	F									L					
nsp14	328	V		F												
nsp14	412	P								H						
nsp15	91	D										Y				
nsp15	259	K					R									
ORF3a	26	S				L	L									
ORF3a	42	P											L	L		

ORF3a	57	Q		H						H		H	H	H	
ORF3a	131	W		L											
ORF3a	171	S		L											
ORF3a	253	S			P										
ORF3a	256	V												I	
ORF7a	82	V					A	A							
ORF7a	93	V		F											
ORF7a	120	T						I							
ORF8	11	T									I	I		K	
ORF8	27		stop												
ORF8	38	P													S
ORF8	51	A										S			S
ORF8	67	S													F
ORF8	92	E			K										
ORF8	121	I		L											
S	5	L									F				
S	13	S								I					
S	18	L		F	F										
S	19	T						R							
S	20	T			N										
S	26	P			S										
S	52	Q									R				
S	67	A													V
S	69	H	-												-
S	70	V	-												-
S	75	G						V							-
S	76	T						I							
S	80	D		A											
S	95	T										I	G	I	I
S	138	D			Y										
S	142	G													D
S	143	V													-
S	144	Y													-
S	145	Y	-											S	-
S	152	W						L	C					N	-
S	154	E					K								-
S	157	F										S			
S	190	R			S										
S	211	N													-
S	212	L													I
S	214	ins													EPE
S	215	D		G/H											
S	241	L	-												
S	242	L	-												
S	243	A	-												
S	246	R						N							
S	247	S						-							
S	248	Y						-							
S	249	L						-							
S	250	T						-							
S	251	P						-							
S	252	G						-							
S	253	D						-				G			
S	339	G													D
S	346	R												K	
S	371	S													L
S	373	S													P
S	375	S													F
S	417	K		N	T										N
S	440	N													K
S	446	G													S
S	452	L						R	R	Q		R			
S	477	S													N
S	478	T				K									K
S	484	E		K	K			Q							A
S	490	F							S		K		K		
S	493	Q													R
S	496	G													S
S	498	Q													R
S	501	N	Y	Y	Y									Y	Y
S	505	Y													H
S	547	T													K
S	570	A	D												
S	614	D	G	G	G	G	G	G	G	G	G	G	G	G	G
S	655	H		Y											Y
S	677	Q									H				
S	679	N													K
S	681	P	H			H	R	R						H	H
S	701	A		V								V			
S	716	T	I												
S	732	T				A									
S	764	N													K
S	769	G							V						
S	796	D													Y
S	856	N													K
S	859	T						N					N		
S	888	F									L				
S	938	L								F					
S	950	D						N					H	N	
S	954	Q													
S	969	N													H
S	981	L													K
S	982	S	A												F
S	1027	T				I									
S	1071	Q						H							
S	1118	D	H												
S	1176	V				F									
S	1191	K								N					

of mutations per variant 22 43 25 11 15 16 21 12 21 12 17 22 21 60

